Development of a tier I screening battery for detecting endocrine-active compounds (EACs)

被引:66
|
作者
Cook, JC
Kaplan, AM
Davis, LG
OConnor, JC
机构
关键词
D O I
10.1006/rtph.1997.1120
中图分类号
DF [法律]; D9 [法律]; R [医药、卫生];
学科分类号
0301 ; 10 ;
摘要
One of the components of our research program is development of a mode-of-action screening battery to detect several different types of endocrine-active compounds (EACs). Our working hypothesis is that a comprehensive short-term in vivo/in vitro battery can be developed to identify endocrine toxicants using a collection of endpoints. The goals of this battery are that it be quick, cost effective, and predictive. The purpose of this battery is to identify potential EACs and to assess their potency in order to prioritize compounds for further study. Two in vivo screens (intact male and ovariectomized female rats) are being evaluated for their ability to detect several different types of endocrine activity. To validate this screen, 15 compounds with known endocrine activities are being used to evaluate a collection of different endpoints for their variability, stability over time, predictiveness, and dose dependency. These positive controls were chosen because they can modulate development, reproduction, or cancer. The advantage of an in vivo screen is that it utilizes a metabolically and physiologically intact system. The male in vivo battery will be used to assess several different types of endocrine activity, primarily by using a comprehensive hormonal battery. The female in vivo battery will be used to identify compounds which are either estrogenic/antiestrogenic or can alter the prolactin pathway. The in vitro portion of the screening battery consists of a yeast transactivation system (YTS). The YTS is being evaluated for its ability to identify compounds which are agonists or antagonists to the estrogen, androgen, or progesterone receptors. The expression of mammalian receptors in yeast allows for assessment of steroid-dependent transcriptional activators. The value of this system is that it can be used as a routine screen for compounds that interact with steroid receptors. Alterations in ligand binding to these receptors can be correlated with alterations in development via masculinization of females and/or feminization of males, decreases in reproductive success, or modulation of cancer incidence from in vivo tests. The in vivo and in vitro screens are designed to be run in parallel with built-in redundancy in order to reduce the probability of false-negative/positive responses. (C) 1997 Academic Press.
引用
收藏
页码:60 / 68
页数:9
相关论文
共 50 条
  • [21] A multi-assay screening approach for assessment of endocrine-active contaminants in wastewater effluent samples
    Metcalfe, Chris D.
    Kleywegt, Sonya
    Letcher, Robert J.
    Topp, Edward
    Wagh, Purva
    Trudeau, Vance L.
    Moon, Thomas W.
    [J]. SCIENCE OF THE TOTAL ENVIRONMENT, 2013, 454 : 132 - 140
  • [22] Evaluation of EPA's Tier 1 Endocrine Screening Battery and recommendations for improving the interpretation of screening results
    Borgert, Christopher J.
    Mihaich, Ellen M.
    Quill, Terry F.
    Marty, M. S.
    Levine, Steven L.
    Becker, Richard A.
    [J]. REGULATORY TOXICOLOGY AND PHARMACOLOGY, 2011, 59 (03) : 397 - 411
  • [23] Effect of neonatal exposure to endocrine-active compounds on epigenetic regulation of gene expression in corpus luteum of gilts
    Witek, Patrycja
    Grzesiak, Malgorzata
    Kotula-Balak, Malgorzata
    Koziorowski, Marek
    Slomczynska, Maria
    Knapczyk-Stwora, Katarzyna
    [J]. THERIOGENOLOGY, 2021, 159 : 45 - 52
  • [24] Metabolomic Analysis of Human Embryonic Stem Cell Derived Germ Like Cells Following Exposure to Endocrine Active Compounds (EACs)
    Henderson, W. M.
    West, F. D.
    Yang, J. Y.
    Stice, S. L.
    Smith, M. A.
    [J]. BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY, 2011, 91 (05) : 337 - 337
  • [25] Development of a physiologically based pharmacokinetic model for estradiol in rats and humans: A biologically motivated quantitative framework for evaluating responses to estradiol and other endocrine-active compounds
    Plowchalk, DR
    Teeguarden, J
    [J]. TOXICOLOGICAL SCIENCES, 2002, 69 (01) : 60 - 78
  • [26] Effect of neonatal exposure to endocrine-active compounds on plasma lipid and steroid concentrations, and morphology of luteal tissue in the adult pig
    Witek, P.
    Grzesiak, M.
    Koziorowski, M.
    Slomczynska, M.
    Knapczyk-Stwora, K.
    [J]. DOMESTIC ANIMAL ENDOCRINOLOGY, 2020, 70
  • [27] Biological regulation of receptor-hormone complex concentrations in relation to dose-response assessments for endocrine-active compounds
    Andersen, ME
    Barton, HA
    [J]. TOXICOLOGICAL SCIENCES, 1999, 48 (01) : 38 - 50
  • [28] Qualitative and quantitative histomorphologic assessment of fathead minnow Pimephales promelas gonads as an endpoint for evaluating endocrine-active compounds:: A pilot methodology study
    Wolf, JC
    Dietrich, DR
    Friederich, U
    Caunter, J
    Brown, AR
    [J]. TOXICOLOGIC PATHOLOGY, 2004, 32 (05) : 600 - 612
  • [29] Endocrine Disruptor Screening Program: Demonstrating Laboratory Proficiency in Conducting Tier I Mammalian In Vivo Assays
    Borghoff, Susan
    Davis, Jeff
    Hackett, Theleria
    Sproul, Pamela
    Moser, Glenda
    [J]. INTERNATIONAL JOURNAL OF TOXICOLOGY, 2010, 29 (01) : 100 - 100
  • [30] Combined effects of dietary phytoestrogen and synthetic endocrine-active compound on reproductive development in Sprague-Dawley rats: Genistein and methoxychlor
    You, L
    Casanova, M
    Bartolucci, EJ
    Fryczynski, MW
    Dorman, DC
    Everitt, JI
    Gaido, KW
    Ross, SM
    Heck, HD
    [J]. TOXICOLOGICAL SCIENCES, 2002, 66 (01) : 91 - 104